Background
Methods
Subjects
Standard neuropathology
In vitro receptor autoradiography
Transmitter | Receptor | [3H]-Ligand | Displacer | Incubation buffer | Preincubation | Main incubation | Final rinsea
|
---|---|---|---|---|---|---|---|
Glutamate | AMPA | AMPA [10 nM] | Quisqualate [10 μM] | 50 mM Tris-acetate (pH 7.2) +100 mM KSCNb
| 3 × 10 minutes, 4 °C | 45 minutes, 4 °C | 1. 4 × 4 seconds 2. Acetone/glutaraldehyde (100 ml/2.5 ml), 2 × 2 seconds, 4 °C |
Kainate | Kainate [9.4 nM] | SYM 2081 [100 μM] | 50 mM Tris-acetate (pH 7.1) + 10 mM Ca2+-acetate | 3 × 10 minutes, 4 °C | 45 minutes, 4 °C | 1. 4 × 4 seconds, 4 °C 2. Acetone/glutaraldehyde (100 ml/2.5 ml), 2 × 2 seconds, 4 °C | |
NMDA | MK-801 [3.3 nM] | (+)MK-801 [100 μM] | 50 mM Tris-acetate (pH 7.2) + 50 μM glutamate + 30 μM glycineb
+ 50 μM spermidineb
| 15 minutes, 4 °C | 60 minutes, 22 °C | 2 × 5 minutes | |
mGlu2/3 | LY341495 [1 nM] |
l-Glutamate [1 mM] | 10 mM phosphate buffer (pH 7.6) + 100 mM KBrb
| 2 × 5 minutes, 22 °C | 60 minutes, 4 °C | 2 × 5 minutes | |
GABA | GABAA
| Muscimol [7.7nM] | GABA [10 μM] | 50 mM Tris-citrate (pH 7.0) | 3 × 5 minutes, 4 °C | 40 minutes, 4 °C | 3 × 3 seconds |
GABAB
| CGP 54626 [2 nM] | CGP 55845 [100 μM] | 50 mM Tris-HCl (pH 7.2) + 2.5 mM CaCl2
| 3 × 5 minutes, 4 °C | 60 minutes, 4 °C | 3 × 2 seconds | |
BZ | Flumazenil [1 nM] | Clonazepam [2 μM] | 170 mM Tris-HCl (pH 7.4) | 15 minutes, 4 °C | 60 minutes, 22 °C | 2 × 1 seconds | |
pBZ | PK 11195 [0.1 nM] | PK 11195 [10 μM] | 50 mM Tris-HCl (pH 7.4) | 15 minutes, 22 °C | 60 minutes, 22 °C | 3 × 5 minutes | |
Acetylcholine | M1
| Pirenzepine [1 nM] | Pirenzepine [2 μM] | Krebs buffer (pH 7.4) + 4 mM KCl + 120 mM NaCl | 15 minutes, 22 °C | 60 minutes, 22 °C | 3 × 4 minutes |
M2
| Oxotremorine-M [1.7 nM] | Carbachol [10 μM] | 20 mM HEPES-Tris (pH 7.5) + 10 mM MgCl2
+ 300 nM pirenzepine | 20 minutes, 22 °C | 60 minutes, 22 °C | 2 × 2 minutes | |
M3
| 4-DAMP [1 nM] | Atropine sulfate [10 μM] | 50 mM Tris-HCl (pH 7.4) + 0.1 mM PMSF + 1 mM EDTA | 15 minutes, 22 °C | 45 minutes, 22 °C | 2 × 5 minutes | |
nACh | Epibatidine [0.5 nM] | Nicotine [100 μM] | 1 mM HEPES (pH 7.5) + 120 mM NaCl + 5.4 mM KCl + 0.8 mM MgCl2
+ 1.8 mM CaCl2
| 20 minutes, 22 °C | 90 minutes, 22 °C | 5 minutes | |
Noradrenaline | α1
| Prazosin [0.2 nM] | Phentolamine mesylate [10 μM] | 50 mM Na+/K+-phosphate buffer (pH 7.4) | 15 minutes, 22 °C | 60 minutes, 22 °C | 2 × 5 minutes |
α2
| UK 14,304 [0.64 nM] | Phentolamine mesylate [10 μM] | 50 mM Tris-HCl (pH 7.7) + 100 μM MnCl2
| 15 minutes, 22 °C | 90 minutes, 22 °C | 5 minutes | |
Serotonin | 5-HT1A
| 8-OH-DPAT [1 nM] | 5-Hydroxytryptamine [1 μM] | 170 mM Tris-HCl (pH 7.4) + 4 mM CaCl2
b
+ 0.01% ascorbateb
| 30 minutes, 22 °C | 60 minutes, 22 °C | 5 minutes |
5-HT2
| Ketanserin [1.14 nM] | Mianserin [10 μM] | 170 mM Tris-HCl (pH 7.7) | 30 minutes, 22 °C | 120 minutes, 22 °C | 2 × 10 minutes | |
Dopamine | D1 | SCH 23390 [1.67 nM] | SKF 83566 [1 μM] | 50 mM Tris-HCl (pH 7.4) + 120 mM NaCl + 5 mM KCl + 2 mM CaCl2
+ 1 mM MgCl2
| 20 minutes, 22 °C | 90 minutes, 22 °C | 2 × 10 minutes |
D2 | Raclopride [0.55 nM] | Butaclamol [1 μM] | 50 mM Tris-HCl (pH 7.4) + 0.1% ascorbate + 150 mM NaCl | 20 minutes, 22 °C | 45 minutes, 22 °C | 6 × 1 minutes | |
Adenosine | A1
| DPCPX [1 nM] | R-PIA [100 μM] | 170 mM Tris-HCl (pH 7.4) + 2 U/L adenosine deaminase + 100 μM Gpp(NH)pb
| 15 minutes, 4 °C | 120 minutes, 22 °C | 2 × 5 minutes |
A2A
| ZM 241385 [0.42 nM] | 2-Chloroadenosine [20 μM] | 170 mM Tris-HCl (pH 7,4) + 2 U/L adenosine deaminase + 10 mM MgCl2
| 2 × 10 minutes, 22 °C | 120 minutes, 22 °C | 2 × 5 minutes |
Statistical analysis
Results
Patients | Control subjects |
p Value | |
---|---|---|---|
n
| 16 | 14 | |
Age at death, years | 72.5 (6.92)a
| 75.7 (10.07) | 0.34 |
Male sex, n (%) | 9 (56) | 9 (64) | 0.8 |
Disease duration, years | 8.2 (2.26)a
| – | – |
Postmortem delay, h, mean (SD) | 6.29 (1.21) | 7.53 (1.31) | 0.01 |
Patient | Age at onset (years) | Age at death (years) | NINDS-SPSP criteria during life | Frontal presentation | Family history | Relevant medication in the last 3 months of life | Brain weight (g) | Tau pathology area 24' | Tau pathology caudate |
---|---|---|---|---|---|---|---|---|---|
1a
| 71 | 73 | Probable | Nonfrontal | Negative | Clonazepam, temazepam, piracetam | 1398 | Grade 3 | Grade 2 |
2 | 66 | 76 | Probable | Frontal | Negative | Oxybutynin, acetylcysteine, thiopental, pancuronium | 1060 | Grade 3 | Grade 2 |
3 | 63 | 68 | Probable | Nonfrontal | Positive | Temazepam, oxybutynin | 1405 | Grade 3 | Grade 4 |
4 | 70 | 79 | Possible | Frontal | Positive | Tolterodine | 1069 | Grade 2 | Grade 2 |
5 | 51 | 60 | Probable | Frontal | Negative | Temazepam | 1256 | Grade 3 | Grade 4 |
6a
| 74 | 80 | Possible | Nonfrontal | Negative | Thiopental, pancuronium | 1100 | Grade 2 | Grade 1 |
7 | 66 | 75 | Possible | Frontal | Negative | Levomeprazine | 1253 | Grade 3 | Grade 1 |
8 | 54 | 64 | Possible | Frontal | Positive | Amantadine | 1290 | Grade 3 | Grade 1 |
9 | 79 | 85 | Possible | Nonfrontal | Negative | Oxazepam, nitrazepam, acetylcysteine | 1175 | Grade 2 | Grade 2 |
10 | 68 | 79 | Probable | Nonfrontal | Negative | Amitriptyline | 922 | Grade 2 | Grade 1 |
11 | 60 | 72 | Possible | Nonfrontal | Positive | Levodopa/carbidopa, amitriptyline | 1045 | Grade 2 | Grade 2 |
12 | 60 | 67 | Probable | Frontal | Positive | Levodopa/carbidopa, lormetazepam, nortriptyline | 1013 | Grade 4 | Grade 2 |
13 | 62 | 70 | Probable | Nonfrontal | Negative | Amantadine, temazepam, diazepam, amitriptyline | 1160 | Grade 2 | Grade 3 |
14a
| 79 | 85 | Possible | Nonfrontal | Negative | Alprazolam, tamsulosin, thiopental, pancuronium | 1305 | Grade 3 | Grade 3 |
15 | 67 | 72 | Possible | Nonfrontal | Positive | Levodopa/carbidopa | 1525 | Grade 2 | Grade 4 |
16 | 61 | 69 | Probable | Frontal | Positive | Midazolam, clozapine | 1270 | Grade 3 | Grade 3 |
Progressive supranuclear palsy cohort vs control subjects
Progressive supranuclear palsy vs. control subjects | Progressive supranuclear palsy, frontal vs. nonfrontal presentation | Progressive supranuclear palsy, mild vs. severe tau pathology | |||||||
---|---|---|---|---|---|---|---|---|---|
Receptor | Control subjects | Patients |
p Value | Frontal | Nonfrontal |
p Value | Mild | Severe |
p Value |
AMPA | 607 (108) | 583 (228) | 0.749 | 477 (248) | 665 (184) | 0.102 | 631 (220) | 503 (238) | 0.290 |
Kainate | 879 (61) | 800 (73) |
0.007
| 783 (70) | 813 (76) | 0.426 | 793 (68) | 812 (85) | 0.628 |
NMDA | 1216 (42) | 1218 (115) | 0.951 | 1210 (122) | 1224 (118) | 0.823 | 1251 (116) | 1163 (99) | 0.413 |
mGlu2/3 | 9295 (625) | 9416 (1455) | 0.799 | 8735 (1746) | 9945 (980) | 0.100 | 9502 (1272) | 9272 (1843) | 0.771 |
GABAA
| 1273 (164) | 1091 (203) | 0.021 | 986 (214) | 1173 (160) | 0.065 | 1133 (178) | 1021 (239) | 0.304 |
GABAB
| 2477 (299) | 2684 (397) | 0.155 | 2529 (402) | 2805 (370) | 0.177 | 2788 (382) | 2511 (389) | 0.184 |
BZ | 1684 (136) | 1458 (330) | 0.023 | 1463 (422) | 1454 (266) | 0.956 | 1635 (284) | 1163 (121) |
0.002
|
pBZ | 1759 (89) | 2050 (347) |
0.005
| 2127 (392) | 1989 (317) | 0.450 | 2154 (365) | 1876 (251) | 0.123 |
M1
| 1174 (35) | 922 (379) | 0.018 | 968 (351) | 886 (418) | 0.686 | 904 (412) | 952 (353) | 0.815 |
M2
| 567 (56) | 497 (127) | 0.063 | 467 (140) | 520 (119) | 0.422 | 501 (158) | 490 (54) | 0.049 |
M3
| 1755 (36) | 1740 (255) | 0.829 | 1753 (309) | 1731 (223) | 0.869 | 1751 (299) | 1723 (183) | 0.843 |
nACh | 200 (42) | 105 (43) |
<0.001
| 97 (30) | 111 (52) | 0.522 | 119 (42) | 82 (38) | 0.094 |
α1
| 339 (28) | 338 (53) | 0.945 | 314 (51) | 356 (50) | 0.123 | 331 (47) | 349 (65) | 0.543 |
α2
| 467 (65) | 510 (92) | 0.199 | 502 (98) | 516 (94) | 0.767 | 498 (91) | 531 (99) | 0.500 |
5-HT1A
| 129 (16) | 135 (27) | 0.543 | 139 (28) | 132 (28) | 0.646 | 139 (33) | 128 (12) | 0.428 |
5-HT2
| 1069 (100) | 976 (142) | 0.074 | 976 (138) | 976 (153) | 0.996 | 1048 (105) | 856 (115) |
0.004
|
D1 | 291 (8) | 332 (49) | 0.010 | 341 (30) | 326 (61) | 0.456 | 349 (53) | 305 (25) | 0.085 |
D2 | 885 (50) | 818 (103) | 0.057 | 765 (108) | 860 (82) | 0.066 | 845 (99) | 774 (102) | 0.188 |
A1
| 1522 (239) | 1952 (288) |
<0.001
| 1966 (327) | 1942 (274) | 0.786 | 1938 (349) | 1977 (167) | 0.806 |
A2A
| 1814 (195) | 2105 (327) | 0.014 | 2112 (409) | 2100 (273) | 0.944 | 2093 (391) | 2124 (212) | 0.863 |
Progressive supranuclear palsy vs. control subjects | Progressive supranuclear palsy, frontal vs. nonfrontal presentation | Progressive supranuclear palsy, mild vs. severe tau pathology | |||||||
---|---|---|---|---|---|---|---|---|---|
Receptor | Control subjects | Patients |
p Value | Frontal | Nonfrontal |
p Value | Mild | Severe |
p Value |
AMPA | 731 (39) | 739 (246) | 0.899 | 681 (216) | 785 (271) | 0.421 | 695 (314) | 773 (191) | 0.546 |
Kainate | 1129 (182) | 1138 (150) | 0.880 | 1102 (162) | 1166 (144) | 0.422 | 1161 (166) | 1120 (145) | 0.602 |
NMDA | 1290 (102) | 1455 (188) |
0.007
| 1531 (155) | 1397 (198) | 0.164 | 1404 (272) | 1495 (79) | 0.350 |
mGlu2/3 | 7932 (1816) | 8576 (1960) | 0.361 | 8462 (1215) | 8665 (2464) | 0.845 | 8136 (2647) | 8918 (1283) | 0.448 |
GABAA
| 1975 (188) | 2125 (241) | 0.070 | 2078 (204) | 2162 (272) | 0.506 | 2232 (323) | 2042 (112) | 0.181 |
GABAB
| 4089 (484) | 5126 (801) |
<0.001
| 4826 (360) | 5360 (982) | 0.176 | 5322 (1155) | 4974 (376) | 0.406 |
BZ | 2686 (296) | 3094 (1028) | 0.164 | 2676 (525) | 3419 (1226) | 0.158 | 3567 (1373) | 2726 (468) | 0.165 |
pBZ | 1698 (227) | 2380 (416) |
<0.001
| 2444 (257) | 2330 (402) | 0.605 | 2452 (464) | 2325 (394) | 0.564 |
M1
| 621 (62) | 505 (175) | 0.023 | 581 (186) | 446 (150) | 0.131 | 458 (204) | 542 (150) | 0.358 |
M2
| 277 (43) | 306 (43) | 0.076 | 285 (29) | 322 (47) | 0.094 | 323 (54) | 293 (29) | 0.185 |
M3
| 1071 (84) | 1135 (127) | 0.117 | 1137 (142) | 1133 (122) | 0.959 | 1123 (129) | 1144 (132) | 0.752 |
nACh | 116 (40) | 102 (40) | 0.325 | 104 (47) | 100 (35) | 0.833 | 111 (38) | 94 (41) | 0.425 |
α1
| 705 (57) | 805 (174) | 0.042 | 803 (204) | 807 (159) | 0.963 | 802 (195) | 808 (167) | 0.949 |
α2
| 1124 (190) | 1288 (220) | 0.039 | 1342 (201) | 1246 (237) | 0.407 | 1337 (221) | 1250 (225) | 0.453 |
5-HT1A
| 542 (53) | 630 (119) | 0.017 | 660 (99) | 606 (133) | 0.380 | 621 (172) | 636 (65) | 0.817 |
5-HT2
| 817 (74) | 963 (170) |
0.006
| 999 (192) | 934 (158) | 0.471 | 1001 (177) | 933 (169) | 0.446 |
D1 | 125 (22) | 143 (25) | 0.050 | 157 (17) | 132 (26) | 0.050 | 136 (29) | 149 (21) | 0.307 |
D2 | 71 (17) | 92 (41) | 0.092 | 75 (19) | 104 (49) | 0.165 | 107 (57) | 80 (18) | 0.191 |
A1
| 1300 (151) | 1476 (318) | 0.069 | 1542 (407) | 1424 (241) | 0.479 | 1413 (281) | 1525 (352) | 0.504 |
A2A
| 120 (9) | 134 (30) | 0.089 | 142 (24) | 128 (35) | 0.392 | 133 (38) | 134 (26) | 0.941 |